首页 | 本学科首页   官方微博 | 高级检索  
     


Randomized,placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
Authors:Wolfgang Oertel MD  Karla Eggert MD  Rajesh Pahwa MD  Caroline M. Tanner MD  PhD  Robert A. Hauser MD  MBA  Claudia Trenkwalder MD  Reinhard Ehret MD  Jean Philippe Azulay MD  Stuart Isaacson MD  Larissa Felt BS  Mary Jean Stempien MD
Affiliation:1. Philipps University, Marburg, Germany;2. University of Kansas Medical Center, Kansas City, Kansas, USA;3. University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA;4. University of South Florida, Tampa, Florida, USA;5. Paracelsus‐Elena‐Klinik, Kassel and Clinic Neurosurgery, University Medical Center, Goettingen, Germany;6. Praxis Neurologie, Berlin, Germany;7. H?pital de la Timone, Marseille, France;8. Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, USA;9. Adamas Pharmaceuticals, Inc., Emeryville, California, USA
Abstract:
Keywords:Parkinson's disease  amantadine  Unified Dyskinesia Rating Scale  levodopa‐induced dyskinesia  randomized controlled trial
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号